Connor, Clark & Lunn Investment Management (CC&L)
CTIC

Connor, Clark & Lunn Investment Management (CC&L)’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,700
Closed -$25K – 1250
2019
Q4 		$25K Buy
+15,700
New +$14.9K ﹤0.01% 905
2017
Q1 		– Sell
-1,150
Closed -$5K – 1080
2016
Q4 		$5K Buy
1,150
+140
+14% +$581 ﹤0.01% 874
2016
Q3 		$4K Hold
1,010
– – ﹤0.01% 826
2016
Q2 		$3K Hold
1,010
– – ﹤0.01% 855
2016
Q1 		$5K Hold
1,010
– – ﹤0.01% 818
2015
Q4 		$12K Buy
+1,010
New +$13.5K ﹤0.01% 803

Other funds holding CTIC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CTIC Position: Q1 2020 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2020, closing a stake of 15,700 shares — an estimated $25K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CTIC in Q4 2015 and held it in 6 quarters. The position peaked at $25K in Q4 2019. 38 funds tracked by Wall St. Rank hold CTIC as of Q1 2020.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2020 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 15,700 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2020, an estimated $25K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 6 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s CTI BioPharma Corp. (DE) Common Stock position peaked at $25K in Q4 2019.
  • 38 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2020.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2020, filed 13 May 2020.